dc.contributor.author | Jacobsen, Cecilie | |
dc.contributor.author | Zivadinov, Robert | |
dc.contributor.author | Myhr, Kjell-Morten | |
dc.contributor.author | Dalaker, Turi Olene | |
dc.contributor.author | Dalen, Ingvild | |
dc.contributor.author | Benedict, Ralph H.B. | |
dc.contributor.author | Bergsland, Niels | |
dc.contributor.author | Farbu, Elisabeth | |
dc.date.accessioned | 2021-08-11T08:51:15Z | |
dc.date.available | 2021-08-11T08:51:15Z | |
dc.date.created | 2021-06-08T11:47:10Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 2055-2173 | |
dc.identifier.uri | https://hdl.handle.net/11250/2767322 | |
dc.description.abstract | Objectives
To identify Magnetic Resonance Imaging (MRI), clinical and demographic biomarkers predictive of worsening information processing speed (IPS) as measured by Symbol Digit Modalities Test (SDMT).
Methods
Demographic, clinical data and 1.5 T MRI scans were collected in 76 patients at time of inclusion, and after 5 and 10 years. Global and tissue-specific volumes were calculated at each time point. For the primary outcome of analysis, SDMT was used.
Results
Worsening SDMT at 5-year follow-up was predicted by baseline age, Expanded Disability Status Scale (EDSS), SDMT, whole brain volume (WBV) and T2 lesion volume (LV), explaining 30.2% of the variance of SDMT. At 10-year follow-up, age, EDSS, grey matter volume (GMV) and T1 LV explained 39.4% of the variance of SDMT change.
Conclusion
This longitudinal study shows that baseline MRI-markers, demographic and clinical data can help predict worsening IPS. Identification of patients at risk of IPS decline is of importance as follow-up, treatment and rehabilitation can be optimized. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | SAGE Publications | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright The Author(s), 2021 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1177/2055217321992394 | |
dc.identifier.cristin | 1914457 | |
dc.source.journal | Multiple Sclerosis Journal - Experimental, Translational and Clinical | en_US |
dc.identifier.citation | Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2021, 7 (1). | en_US |
dc.source.volume | 7 | en_US |
dc.source.issue | 1 | en_US |